Breaking News
10 hours ago
Pharma Now Editorial Team

Pharma Now Editorial Team
Pharma Now Editorial Team
Pharma Now Editorial Team
Pharma Now Editorial Team
FDA approves selumetinib granules for NF1 patients from age 1, using bioavailability bridging rather than a new efficacy trial.
Pharma Now Editorial Team

FDA issues fifth ASCENIV approval letter for ADMA Biologics and extends expiry on six 2019-2020 lots, with compliance implications for biologics manufacturers.
Pharma Now Editorial Team

Supreme Court restores mifepristone access via telehealth, mail, and pharmacies, with REMS compliance obligations unchanged.
Pharma Now Editorial Team

Vanda Pharmaceuticals launches NEREUS, the first new motion sickness treatment approved in over 40 years, now available at U.S. retail pharmacies.
Pharma Now Editorial Team
